% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • searchingforgains searchingforgains Jul 25, 2011 8:47 AM Flag

    European guideline

    According to the new guidelines, although there are several tests that provide prognostic information, where uncertainty remains, only Oncotype DX is included as the multi-gene test that "may also be used where available to predict chemotherapy responsiveness" in estrogen receptor-positive breast cancer. In addition to existing studies that have already been conducted to validate Oncotype DX®, a major ongoing prospective trial called TAILORx will provide further insight on the predictive and prognostic value of the test.

    "Inclusion in the St. Gallen's guidelines represents an important recognition of the value of Oncotype DX in enabling more individualized treatment decisions by the international medical community," says Christer Svedman, director, medical affairs in Europe, Genomic Health.

29.66-0.07(-0.24%)Oct 21 4:00 PMEDT